When we think PHC, we usually refer to the identification of predictive or prognostic markers, maybe combination therapies, or comprehensive genomic profiling. But PHC is much bigger than that. It’s about establishing a solid health-economic basis for the best possible patient care, from diagnostic technology to therapeutic intervention.
The project that currently consumes most of my time is the Shining Tower initiative. It’s about identifying the data gaps, the evidence gaps, the policy gaps and then systematically working on them. It aims to address current limitations in the German healthcare system, in particular when it comes to providing the best possible personalised care for cancer patients. We face so many hurdles: from infrastructure and data privacy, to access, reimbursement, and regulatory issues. With global support, the Shining Tower team delivers crucial input to discussions with policymakers, payers, societies and regulators. I was instrumental in getting Germany on the shortlist of 10 countries that were selected for further investment through my input as the medical specialist in these multi-disciplinary teams.